Press Releases
Date picker
Category
Results per page
Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting
BackgroundNovakand Pharma AB (”Novakand” or the ”Company”) announced on February 24, 2026, that Nasdaq had rejected Novakand's application for continued listing on First North Growth Market following the planned reverse…
The board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines
On February 24, 2026, Novakand Pharma AB (publ) (“Novakand” or “the Company”) announced that Nasdaq has rejected Novakand’s application for approval of continued listing on the First North Growth Market…
Novakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines
Novakand Pharma AB (publ) (“Novakand” or “the Company”) has previously reported that the Company has entered into a share purchase agreement with the shareholders of SVF Vaccines AB (“SVF”) for…
Novakand Pharma enters into share purchase agreement with SVF Vaccines regarding a reverse takeover
Novakand Pharma AB (publ) (“Novakand” or “the Company”) today reports that the Company has entered into a share purchase agreement with the shareholders of SVF Vaccines AB (“SVF”), whereby Novakand…
Novakand Pharma enters Letter of Intent with SVF Vaccines regarding a reverse takeover
Regulatory
Novakand Pharma AB (publ) (“Novakand” or “the Company”) today announces that the Company has entered into a non-binding letter of intent (“LOI”) with SVF Vaccines AB (“SVF”) including terms and…
Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the third quarter 2025Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 4,0 million (SEK 10,2 million).Operating…
Novakand Pharma provides an update on the ongoing reverse take over process
On September 18, 2025 Novakand Pharma AB (publ) announced that the board had decided to initiate a process to identify potential stakeholders for a reverse take over. The company now…
Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board
Regulatory
Novakand Pharma AB (publ) today announces that CEO Peter Selin has decided to resign as CEO of the company. The decision is made in mutual agreement with the Board of…
Kancera AB changes name to Novakand Pharma AB
Regulatory
Kancera AB (publ) today announces that the company is changing its name to Novakand Pharma AB (publ). The name change was resolved at the Annual General Meeting on May 26,…
Kancera initiates process to seek stakeholders for a reverse take over
Regulatory
Kancera AB (publ) (“Kancera”) today announces that the board has decided to initiate a process to seek potential stakeholders for a reverse take over of the company with the aim…